Get started
Author

Helena Verdaguer

Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors
2022 · Rocio Garcia-Carbonero, Miriam Bazan-Peregrino, et al. · Journal for ImmunoTherapy of Cancer · 105
PDF
The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models
2024 · Andrea Herencia-Ropero, Alba Llop-Guevara, et al. · Genome Medicine · 84
PDF
Ramucirumab in metastatic colorectal cancer: evidence to date and place in therapy
2016 · Helena Verdaguer, Josep Tabernero, et al. · Therapeutic Advances in Medical Oncology · 81
PDF
ESMO Scale for Clinical Actionability of Molecular Targets Driving Targeted Treatment in Patients with Cholangiocarcinoma
2022 · Helena Verdaguer, Tamara Saurí, et al. · Clinical Cancer Research · 80
PDF
Analysis of mutant allele fractions in driver genes in colorectal cancer – biological and clinical insights
2017 · Rodrigo Dienstmann, Elena Elez, et al. · Molecular Oncology · 60
PDF
Predictive and prognostic biomarkers in personalized gastrointestinal cancer treatment
2017 · Helena Verdaguer, Tamara Saurí, et al. · Journal of Gastrointestinal Oncology · 32
PDF
Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation
2022 · Queralt Serra-Camprubí, Helena Verdaguer, et al. · Clinical Cancer Research · 26
PDF
The role of PIGF blockade in the treatment of colorectal cancer: overcoming the pitfalls
2019 · Teresa Macarulla, Clara Montagut, et al. · Expert Opinion on Biological Therapy · 26
Gene mutational profile of BRCAness and clinical implication in predicting response to platinum-based chemotherapy in patients with intrahepatic cholangiocarcinoma
2022 · Margherita Rimini, Teresa Macarulla, et al. · European Journal of Cancer · 25
Molecular profile and its clinical impact of IDH1 mutated versus IDH1 wild type intrahepatic cholangiocarcinoma
2022 · Margherita Rimini, Carles Fabregat-Franco, et al. · Scientific Reports · 24
PDF
Advances in the systemic treatment of therapeutic approaches in biliary tract cancer
2022 · O. Mirallas, D. López-Valbuena, et al. · ESMO Open · 23
Quality of life of patients with metastatic pancreatic adenocarcinoma initiating first-line chemotherapy in routine practice
2020 · Berta Laquente, Teresa Macarulla, et al. · BMC Palliative Care · 22
PDF
Next-generation sequencing analysis of cholangiocarcinoma identifies distinct IDH1-mutated clusters
2022 · Margherita Rimini, Eleonora Loi, et al. · European Journal of Cancer · 21
PDF
A phase III randomized study of first-line NUC-1031/cisplatin vs. gemcitabine/cisplatin in advanced biliary tract cancer
2025 · Jennifer J. Knox, Mairéad G. McNamara, et al. · Journal of Hepatology · 18
NUC-1031/cisplatin versus gemcitabine/cisplatin in untreated locally advanced/metastatic biliary tract cancer (NuTide:121)
2020 · Mairéad Geraldine McNamara, Lipika Goyal, et al. · Future Oncology · 17
PDF
Clinical Outcomes After Progression on First-Line Therapies in IDH1 Mutated Versus Wild-Type Intrahepatic Cholangiocarcinoma Patients
2023 · Margherita Rimini, Carles Fabregat-Franco, et al. · Targeted Oncology · 14
Emerging Treatment Strategies in Pancreatic Cancer
2021 · Andrew Trunk, Laura Miotke, et al. · Pancreas · 11
ACT-Discover: identifying karyotype heterogeneity in pancreatic cancer evolution using ctDNA
2023 · Ariana Huebner, James R. M. Black, et al. · Genome Medicine · 9
PDF
New Horizons in the Treatment of Metastatic Pancreatic Cancer: A Review of the Key Biology Features and the Most Recent Advances to Treat Metastatic Pancreatic Cancer
2018 · Helena Verdaguer, Alvaro Arroyo, et al. · Targeted Oncology · 8
Comprehensive profiling of biliary tract cancers (BTC) to reveal molecular heterogeneity with implications for matched targeted therapies (MTT).
2016 · Tamara Sauri, Teresa Macarulla, et al. · Journal of Clinical Oncology · 7
O-2 Phase III study of NUC-1031 + cisplatin vs gemcitabine + cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121)
2023 · J. Knox, I. Bazin, et al. · Annals of Oncology · 6
PDF
Experiencia inicial en el tratamiento del adenocarcinoma de páncreas borderline resectable
2017 · Juli Busquets, Juan Fabregat, et al. · Cirugía Española · 5
Neoadjuvant sunitinib plus exemestane in post-menopausal women with hormone receptor-positive/HER2-negative early-stage breast cancer (SUT_EXE-08): a phase I/II trial
2024 · Bartomeu Fullana, Serafín Morales, et al. · Scientific Reports · 4
Abstract CT096: Phase 1 study of RO7119929 (TLR7 agonist prodrug) in patients (pts) with advanced primary or metastatic liver cancers
2023 · Changhoon Yoo, Helena Verdaguer, et al. · Cancer Research · 4
Phase III study of NUC-1031 + cisplatin vs gemcitabine + cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121).
2021 · Jennifer J. Knox, Mairead Geraldine McNamara, et al. · Journal of Clinical Oncology · 4
Works count: 101
Citation count: 755
H-index: 15
I10-index: 17
Year
Topic
Type